Table 2 Pathological characteristics of patients
Variable | Consolidation-to-tumor ratio | |||||||
|---|---|---|---|---|---|---|---|---|
Overall (n = 944) | 0% (n = 89) | 0–25% (n = 81) | 25–50% (n = 83) | 50–75% (n = 116) | 75–100% (n = 201) | 100% (n = 374) | ||
Pathologic size | ||||||||
Total Size (mm, mean ± SD) | 20.8 ± 7.8 | 17.1 ± 5.9 | 17.6 ± 6.8 | 19.2 ± 7.3 | 22.5 ± 9.1 | 22.2 ± 8.1 | 21.5 ± 7.3 | 0.036 |
Invasive size (mm, mean ± SD) | 18.9 ± 8.3 | 12.2 ± 7.0 | 13.2 ± 6.6 | 14.8 ± 6.6 | 19.3 ± 9.0 | 21.0 ± 7.9 | 21.4 ± 7.4 | 0.014 |
Histologic type | ||||||||
ADC | 852 (90.3%) | 89 (100.0%) | 81 (100.0%) | 83 (100.0%) | 114 (98.3%) | 194 (96.5%) | 291 (77.8%) | 0.000 |
SqCC | 66 (7.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 5 (2.5%) | 61 (16.3%) | |
Others | 26 (2.8%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (1.7%) | 2 (1.0%) | 22 (5.9%) | |
Predominant histologic pattern of ADC (n = 787) | 0.000 | |||||||
Lepidic | 60 (6.4%) | 26 (31.0%) | 13 (16.9%) | 8 (10.5%) | 5 (4.7%) | 6 (3.3%) | 2 (0.8%) | |
Acinar | 548 (58.1%) | 50 (59.5%) | 58 (75.3%) | 57 (75.0%) | 93 (87.7%) | 142 (78.0%) | 148 (56.5%) | |
Papillary | 97 (10.3%) | 8 (9.5%) | 6 (7.8%) | 10 (13.2%) | 6 (5.7%) | 22 (12.1%) | 45 (17.2%) | |
Solid | 50 (5.3%) | 0 (0.0%) | 0 (0.0%) | 1 (1.3%) | 0 (0.0%) | 2 (1.1%) | 47 (17.9%) | |
Micro-papillary | 16 (1.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (1.9%) | 8 (4.4%) | 6 (2.3%) | |
Complex (cribriform etc.) | 16 (1.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (1.1%) | 14 (5.3%) | |
Grade of predominant histologic pattern of ADC* (n = 787) | 0.000 | |||||||
Low (Lepidic) | 60 (7.6%) | 26 (31.0%) | 13 (16.9%)) | 8 (10.5%) | 5 (4.7%) | 6 (3.3%) | 2 (0.8%) | |
Intermediate (Acinar, Papillary) | 645 (82.0%) | 58 (69.0%) | 64 (83.1%) | 67 (88.2%) | 99 (93.4%) | 164 (90.1%) | 193 (73.7%) | |
High (Solid, Micro-papillary, Complex) | 82 (10.4%) | 0 (0%) | 0 (0%) | 1 (1.3%) | 2 (1.9%) | 12 (6.6%) | 67 (25.6%) | |
Pathologic N stage | 0.000 | |||||||
N0 | 837 (88.7%) | 84 (94.4%) | 77 (95.1%) | 81 (97.6%) | 113 (97.4%) | 181 (90.1%) | 301 (80.5%) | |
N1 | 44 (4.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.9%) | 11 (5.5%) | 32 (8.6%) | |
N2 | 41 (4.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.9%) | 7 (3.5%) | 33 (8.8%) | |
Unknown | 22 (2.3%) | 5 (5.6%) | 4 (4.9%) | 2 (2.4%) | 1 (0.9%) | 2 (1.0%) | 8 (2.1%) | |
Tumor-infiltrating lymphocyte (TIL) | ||||||||
Unknown | 137 | 11 (12.4%) | 6 (7.4%) | 12 (14.5%) | 14 (12.1%) | 30 (14.9%) | 64 (17.1%) | |
Low | 189 | 8 (9.0%) | 9 (11.1%) | 8 (9.6%) | 16 (13.8%) | 39 (19.4%) | 109 (29.1%) | |
Moderate | 218 | 19 (21.3%) | 15 (18.5%) | 25 (30.1%) | 31 (26.7%) | 41 (20.4%) | 87 (23.3%) | |
High | 400 | 51 (57.3%) | 51 (63.0%) | 38 (45.8%) | 55 (47.4%) | 91 (45.3%) | 114 (30.5%) | |